This structural selectivity means AOD-9604 cannot trigger the intracellular signaling cascades normally initiated by growth hormone receptor activation

How it helps disc herniation specifically: Upregulates tendon-related growth factors BPC-157 activates the Egr-1 transcription factor, which drives collagen synthesis in fibrous tissue including the annulus fibrosus Promotes angiogenesis increases VEGF expression, improving blood supply to the avascular disc environment Neuroprotective effects multiple rodent studies show BPC-157 accelerates peripheral nerve regeneration and protects against nerve compression injury Systemic anti-inflammatory suppresses pro-inflammatory cytokine cascades without the immunosuppressive side effects of steroids Protocol: Dose: 250500mcg/day subcutaneous injection Injection site: Lower abdomen or closest accessible subQ site to the injury (though systemic distribution means proximity matters less than for localized joint issues) Duration: 68 weeks loading phase, reassess at week 8 Most people notice reduced nerve pain and improved mobility within 24 weeks
doi: 10.1016/j.isci.2023.106935
Our Quality Standards Strict sourcing, batch tracking, and purity-focused manufacturing protocols
Learn about our quality process Related products CJC-1295 (No DAC)/Ipamorelin Blend 5+5mg Summary Description: The CJC-1295 (no DAC) + Ipamorelin peptide blend merges two potent growth hormone secretagogues to synergistically enhance physiologic GH pulsatility
286.11 (iodide salt) Amino Acid Count: N/A small molecule Amino Acid Sequence: N/A small molecule Synonyms / Other Names: 5-Amino-1-MQ, NNMTi, 5-amino-1-methylquinolinium Appearance: Orange to yellow powder Purity: 98% (HPLC) Solubility: Soluble in water and DMSO Storage Sealed: Freeze 20 C, sealed, away from light & moisture